If your PSA is raised, you may wonder whether it’s a sign of prostate cancer or caused by an enlarged or inflamed prostate. The Prostate Health Index (PHI) is a blood test that combines total PSA, free PSA and a marker called p2PSA to estimate your risk of prostate cancer, particularly clinically significant cancer.
Your PHI result can help you and your doctor decide whether further investigation, such as a biopsy, may be worthwhile, but it cannot diagnose cancer on its own. In the UK, NICE recommends multiparametric MRI as the first-line investigation for suspected clinically localised prostate cancer, and PHI isn’t routinely recommended as its replacement.
What Exactly Is the Prostate Health Index?
Your Prostate Health Index (PHI) is a blood-test score calculated using three PSA-related measurements: total PSA, free PSA and p2PSA. By looking at how these markers relate to each other, PHI can help your doctor assess your risk of prostate cancer more accurately than total PSA alone.
A higher PHI generally suggests a greater chance of cancer being found on biopsy, while a lower score suggests lower risk. However, your result cannot confirm or rule out cancer, so your doctor will consider it alongside your other test results before recommending further investigation.
What Are Total PSA, Free PSA and [-2]proPSA?
When you have a PSA blood test, your total PSA includes both PSA that circulates freely in your blood and PSA attached to other proteins. Your free PSA is the amount that circulates on its own. If you have benign prostate enlargement, you may have a higher proportion of free PSA, while prostate cancer may be associated with a lower proportion.
Your doctor can also assess p2PSA, a precursor form of PSA that may be more closely associated with prostate cancer than total PSA alone. The PHI test combines all three measurements to give you a clearer estimate of your cancer risk than total PSA alone. It can help you and your doctor decide whether you may need further investigation.
How Is PHI Calculated?
Your PHI score is calculated automatically by the laboratory using your p2PSA, free PSA and total PSA results. You don’t need to work out the formula yourself. By combining these measurements in a laboratory formula, PHI assesses the relationship between your PSA markers rather than relying on total PSA alone.
For example, two men can have the same total PSA of 6 ng/mL but different PHI scores because their other marker levels differ. This helps your doctor assess whether your results suggest a higher or lower risk of prostate cancer.
Why Was PHI Developed?

If your PSA is raised, you may worry about prostate cancer, but conditions such as an enlarged prostate (BPH) or inflammation can also increase your levels. This means you may undergo a biopsy even when you don’t have clinically significant cancer.
PHI was developed to give you and your doctor a clearer picture of your risk before deciding on a biopsy. By combining different PSA-related markers, it can help identify whether you may need further investigation or whether monitoring could be a reasonable option.
PSA, PHI, MRI and Biopsy: What Does Each Test Do?
| Test | What it assesses | Main role | Diagnoses cancer? |
| PSA | Total prostate-specific antigen in blood | Initial risk assessment | No |
| PHI | Total PSA, free PSA and p2PSA | Refines biochemical risk in selected men | No |
| Prostate MRI | Areas within the prostate suspicious for significant cancer | Helps determine whether/where to biopsy | No |
| Prostate biopsy | Prostate tissue under a microscope | Confirms cancer and Grade Group | Yes |
How Is PHI Different From a Standard PSA Test?
A standard PSA test measures your PSA level, while PHI combines total PSA, free PSA and p2PSA to give you a more detailed estimate of your prostate cancer risk. Research has shown that PHI can improve cancer-risk assessment in selected men with moderately raised PSA levels.
PHI doesn’t replace your usual PSA test; it builds on it. Your doctor may use PSA to identify a potential concern, PHI to refine your risk and MRI to look for suspicious areas in your prostate. Together, these results can help guide your next steps.
Who Might Be Considered for a PHI Test?
PHI is most useful when additional risk information could genuinely influence whether further investigation is needed. Important considerations include:
- Raised PSA: PHI was originally developed for men whose PSA is elevated but does not provide a clear answer.
- Age: The original FDA indication applies to men aged 50 years or older.
- PSA range: FDA approval covers total PSA from 4.0 to 10.0 ng/mL.
- Digital rectal examination: The original approved population has DRE findings that are not suspicious for cancer.
- Uncertain biopsy decision: PHI is most useful when there is genuine uncertainty about whether biopsy is warranted.
- MRI findings: In modern practice, PHI may be interpreted alongside MRI rather than replacing it.
- Clinical risk factors: PSA trend, prostate size, family history and overall health remain relevant.
- UK pathway: PHI is not a routine step in the NICE diagnostic pathway.
- Previous negative biopsy: NICE specifically advises against PHI in people being investigated after a negative or inconclusive biopsy.
The test adds the most value when its result is likely to change the next clinical decision rather than when other findings have already established a clearly high or low level of concern.
What Does a PHI Score Mean?
Your PHI score helps estimate your risk of prostate cancer, but it is an index rather than a percentage probability. A higher score generally suggests a greater chance of finding cancer, while a lower score suggests lower risk. However, no single cut-off can reliably confirm or rule out cancer for everyone.
Your doctor will interpret your score alongside your PSA trend, age, prostate size, family history and MRI findings. This helps you decide whether a biopsy or continued monitoring may be appropriate for your situation.
Does a High PHI Score Mean You Definitely Have Prostate Cancer?

If your PHI score is high, you may feel worried, but it doesn’t mean you definitely have prostate cancer or indicate its Grade Group. Some men with high scores have benign biopsy results, while others may have low-risk cancer.
Your doctor will use your PHI result alongside your other test findings to decide whether you need further investigation. Only a biopsy can confirm a prostate cancer diagnosis, so don’t treat your score alone as proof that you have cancer.
Does a Low PHI Score Rule Out Prostate Cancer?
If your PHI score is low, your risk of prostate cancer may be lower, but it doesn’t rule out cancer completely. Some men with reassuring scores can still have clinically significant cancer, so your result shouldn’t be the only factor guiding your care.
If your PSA continues to rise, your MRI shows a suspicious area or you have a strong family history, your doctor may recommend further investigation despite a low score. Remember, PHI reflects your risk at that time, not a guarantee that you’ll remain cancer-free in the future.
Clinical Note
A low PHI may be reassuring when PSA history, examination and imaging are also low risk. However, a biomarker result should not be used in isolation to dismiss a suspicious MRI, persistent PSA concern or other important risk factors.
Your specialist should therefore interpret PHI as one part of a wider assessment rather than using a single PHI threshold as an automatic biopsy decision.
Is PHI Better Than PSA Alone?
Your PHI test can often assess prostate cancer risk more accurately than a standard PSA test. A 2025 review found that combining total PSA, free PSA and p2PSA improved cancer-risk assessment and could help you avoid an unnecessary biopsy.
However, PHI isn’t perfect, and results can vary depending on your population, prostate size and other risk factors. Your doctor should interpret your score alongside your overall clinical picture rather than relying on one cut-off alone.
Can PHI Reduce Unnecessary Prostate Biopsies?
If your PSA is raised but your PHI suggests a lower risk, your doctor may decide that you can delay a biopsy and continue monitoring. Research suggests PHI can help some men without cancer avoid unnecessary procedures while still identifying those who may need further investigation.
However, biopsy decisions now often involve MRI as well. Your doctor will consider whether PHI adds useful information alongside your MRI findings and other risk factors before deciding on your next step.
Research Insight
Current European Association of Urology (EAU) guidance cites a prospective multicentre study in which using a PHI threshold above 30 to decide who proceeded to MRI and biopsy could have avoided both investigations in approximately 25% of the men studied.
However, this strategy could also have missed approximately 8% of Grade Group 2 or higher cancers detected in the study. This shows why biomarker thresholds cannot simply be chosen to maximise avoided investigations: reductions in MRI or biopsy must be balanced against the risk of missing clinically significant cancer.
How Does PHI Work Alongside Prostate MRI?

Your PHI test measures your biochemical risk of prostate cancer, while MRI looks for suspicious areas inside your prostate. Using both may give your doctor additional information about your risk compared with interpreting either test alone.
Recent studies suggest that PHI can add useful information to MRI findings, even when the scan looks less suspicious. However, there’s no single PHI cut-off that works for everyone, so your doctor will consider both results alongside your other risk factors before recommending a biopsy.
Could PHI Be Used Before MRI?
If your PSA is raised, your doctor may consider using PHI to get a clearer idea of your cancer risk before recommending an MRI. If your score suggests a lower risk, you may be able to discuss whether further testing can wait, while a higher score may support moving ahead with imaging.
Researchers are exploring whether this approach could help you avoid an unnecessary MRI without missing significant cancer. However, MRI remains the standard first-line investigation in the UK, so PHI isn’t currently a routine replacement for the NHS pathway.
UK Guidance Note
NICE recommends multiparametric MRI as the first-line investigation for people with suspected clinically localised prostate cancer. MRI results are then used with wider clinical risk to determine whether prostate biopsy should be offered.
PHI is not included as a routine pre-MRI triage test in this pathway. NICE also specifically recommends against PHI when someone is being investigated after a negative or inconclusive previous prostate biopsy.
Does PHI Work When PSA Is Above 10 ng/mL?
If your PSA is above 10 ng/mL, PHI may still help assess your risk of significant prostate cancer. A study published online in 2025 and in a 2026 journal issue found that higher PHI scores were associated with a greater likelihood of Grade Group 2 or higher cancer in men with PSA between 10 and 20 ng/mL. MRI also provided useful additional information.
However, these findings come from a specific study group, so you shouldn’t use its cut-offs to interpret your own results. Your doctor will consider your PHI, PSA and MRI findings together to decide whether you need a biopsy.
Evidence Note
The original FDA-approved PHI population consists of men aged at least 50 with PSA 4–10 ng/mL and a non-suspicious digital rectal examination.
A more recent study of 456 biopsy-naïve men with PSA 10–20 ng/mL found that PHI remained strongly associated with Grade Group 2 or higher cancer. However, this study was retrospective and outside the original FDA-approved PSA range.
What Is the Current European Guideline Position?
European Association of Urology (EAU) guidelines recognise PHI as a blood test that may help you assess your prostate cancer risk and potentially avoid an unnecessary biopsy. It combines total PSA, free PSA and p2PSA to provide additional information when your PSA is raised.
However, MRI has a stronger recommendation than additional blood or urine biomarkers in European guidance. Your doctor will consider whether PHI could help in your situation, depending on your existing test results, local availability and the next steps in your diagnostic pathway.
Is PHI Routinely Recommended in the UK?

If you’re being investigated for prostate cancer in the UK, you’ll usually have a multiparametric MRI first, as recommended by NICE. PHI isn’t routinely included in this diagnostic pathway, so you may not be offered it as part of your standard NHS assessment.
If you’ve already had a negative or inconclusive biopsy, NICE specifically advises against using PHI in that situation. Your doctor can still assess your risk using your PSA history, MRI findings and other clinical factors to help decide what you may need next.
Myth vs Fact
| Myth | Fact |
| PHI diagnoses prostate cancer. | Only biopsy can confirm prostate cancer. |
| A PHI score of 40 means a 40% cancer risk. | PHI is an index value, not a percentage probability. |
| PHI is simply another total PSA test. | It combines total PSA, free PSA and p2PSA. |
| A low PHI completely rules out significant cancer. | Clinically significant cancer can still occur despite a low result. |
| A high PHI proves you have aggressive cancer. | It increases estimated risk but does not establish a diagnosis or Grade Group. |
| PHI can replace MRI. | MRI remains first-line in the standard NICE pathway. |
| PHI is routinely recommended after a negative biopsy. | NICE specifically recommends against it in that setting. |
| Evidence in PSA 10–20 ng/mL is part of the original FDA indication. | The original approved PSA range is 4–10 ng/mL. |
Key Takeaways
- PHI combines total PSA, free PSA and p2PSA.
- It is an index score, not a percentage probability.
- Higher PHI values are generally associated with greater prostate-cancer risk.
- PHI cannot diagnose or completely exclude cancer.
- Research suggests PHI improves discrimination compared with total PSA alone.
- Its strongest established evidence is in men with moderately raised PSA.
- The original FDA indication applies to men aged 50 or older, PSA 4–10 ng/mL, and a non-suspicious DRE.
Frequently Asked Questions
1. What is the Prostate Health Index (PHI) test?
The PHI test is a blood test that combines total PSA, free PSA and p2PSA to estimate your risk of prostate cancer, particularly clinically significant cancer.
2. How is PHI different from a standard PSA test?
A standard PSA test measures total PSA, while PHI combines three PSA-related markers to provide a more detailed estimate of your prostate cancer risk.
3. What does a high PHI score mean?
A high PHI score suggests a greater chance of finding prostate cancer on biopsy, but it doesn’t confirm cancer. Your doctor will consider your other test results before recommending further investigation.
4. Can a low PHI score rule out prostate cancer?
No. A low score suggests a lower risk but cannot rule out cancer completely. Your PSA trend, MRI findings and family history may still indicate a need for further tests.
5. Who might benefit from a PHI test?
You may benefit if your PSA is raised and your doctor needs more information to decide whether a biopsy is worthwhile. In the US, the test is approved for certain men aged 50 or older with PSA levels between 4 and 10 ng/mL and a non-suspicious rectal examination.
6. Can the PHI test help you avoid a prostate biopsy?
PHI may help your doctor identify men at lower risk who could continue monitoring instead of having an immediate biopsy. However, your doctor must consider the possibility of missing significant cancer.
7. Is PHI more accurate than PSA alone?
PHI can improve prostate cancer risk assessment in selected men compared with total PSA alone. However, it isn’t perfect and should be interpreted alongside your other clinical findings.
8. Can PHI be used alongside prostate MRI?
Yes. PHI estimates your biochemical risk, while MRI looks for suspicious areas in your prostate. Your doctor can use both results to help decide whether a biopsy is needed.
9. Does PHI work when your PSA is above 10 ng/mL?
Research suggests PHI may provide useful risk information in some men with PSA levels above 10 ng/mL. However, your doctor should interpret your result alongside your MRI and other clinical findings.
10. Is the PHI test routinely recommended on the NHS in the UK?
PHI isn’t part of the routine NICE prostate cancer diagnostic pathway in the UK. Multiparametric MRI is generally the recommended first-line investigation when localised prostate cancer is suspected.
Final Thoughts: Is the PHI Test Right for You?
The Prostate Health Index (PHI) test can help you understand your risk of clinically significant prostate cancer by combining total PSA, free PSA and p2PSA into a single score. It may help you and your doctor decide whether further investigation, such as a prostate biopsy, is worthwhile. However, PHI cannot confirm or rule out cancer completely, and it isn’t part of the routine NICE diagnostic pathway in the UK. Your doctor will consider your PHI score alongside your PSA history, MRI findings and individual risk factors before recommending your next steps.
If you’re concerned about your PSA results or prostate cancer risk, you can contact Prostate Clinic London for specialist advice. Your consultation can help you discuss further tests, understand your diagnostic options and receive guidance tailored to your individual needs.
References:
- Lee, I.T. et al. (2025) ‘Optimizing prostate cancer care: clinical utility of the Prostate Health Index’, The Prostate. Available at: https://pubmed.ncbi.nlm.nih.gov/40745917/
- Sekine, Y. et al. (2025) ‘Utility of combining Prostate Health Index and magnetic resonance imaging for the diagnosis of prostate cancer’, International Journal of Urology. Available at: https://pubmed.ncbi.nlm.nih.gov/40098218/
- Holzbeierlein, H. et al. (2026) ‘Performance of the Prostate Health Index Test in Men With Prostate Specific Antigen Levels Between 10 and 20 ng/mL’, Urology, 208, pp. 112–116. Available at: https://pubmed.ncbi.nlm.nih.gov/41421556/
- Agnello, L. et al. (2024) ‘Prostate Health Index (PHI) as a triage tool for reducing unnecessary magnetic resonance imaging (MRI) in patients at risk of prostate cancer’, Clinical Biochemistry. Available at: https://pubmed.ncbi.nlm.nih.gov/38583655/
- National Institute for Health and Care Excellence (2021) Prostate cancer: diagnosis and management. NICE guideline NG131. Available at: https://www.nice.org.uk/guidance/ng131
- U.S. Food and Drug Administration (2012) Beckman Coulter Prostate Health Index (PHI): Premarket Approval P090026. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P090026